Table 1 Demographics of the diagnosed GD and control cohorts
Diagnosed with GD N = 756 | Controls N = 1,328,000 | p value# | |
|---|---|---|---|
Age at index (years) | < 0.001 | ||
Mean (SD) | 44 (22) | 40 (24) | |
Min | 0 | 0 | |
Median (Q1–Q3) | 45 (27–61) | 39 (21–58) | |
Max | 87 | 89 | |
Age in class | < 0.001 | ||
0–9 | 58 (7.7%) | 175,841 (13.2%) | |
10–19 | 57 (7.5%) | 133,630 (10.1%) | |
20–29 | 93 (12.3%) | 181,418 (13.7%) | |
30–39 | 107 (14.2%) | 174,281 (13.1%) | |
40–49 | 114 (15.1%) | 167,545 (12.6%) | |
50–59 | 121 (16.0%) | 188,475 (14.2%) | |
60–69 | 110 (14.6%) | 148,014 (11.1%) | |
70–79 | 72 (9.5%) | 102,493 (7.7%) | |
80–89 | 24 (3.2%) | 56,303 (4.2%) | |
Race | < 0.001 | ||
African American | 29 (3.8%) | 128,439 (9.7%) | |
Asian | 2 (0.3%) | 28,957 (2.2%) | |
Caucasian | 624 (82.5%) | 830,948 (62.6%) | |
Other/unknown | 101 (13.4%) | 339,656 (25.6%) | |
Ethnicity | < 0.001 | ||
Hispanic | 37 (4.9%) | 84,613 (6.4%) | |
Not Hispanic | 621 (82.1%) | 877,906 (66.1%) | |
Unknown | 98 (13.0%) | 365,481 (27.5%) | |
Region | < 0.001 | ||
Midwest | 193 (25.5%) | 565,677 (42.6%) | |
Northeast | 345 (45.6%) | 189,864 (14.3%) | |
South | 133 (17.6%) | 352,187 (26.5%) | |
West | 61 (8.1%) | 137,904 (10.4%) | |
Other/unknown | 24 (3.2%) | 82,368 (6.2%) | |
Death | |||
0 | 716 (94.7%) | 1,258,157 (94.7%) | |
1 | 40 (5.3%) | 69,843 (5.3%) | |
Coverage (years) | < 0.001 | ||
Mean (SD) | 7 (3) | 5 (4) | |
Min | 0.17 | 0 | |
Median (Q1–Q3) | 7 (4–10) | 4 (0–8) | |
Max | 12.75 | 12.82 | |
Look-back period (years) | < 0.001 | ||
Mean (SD) | 3 (3) | 2 (2) | |
Min | 0 | 0 | |
Median (Q1–Q3) | 2 (1–5) | 1 (0–2) | |
Max | 12.36 | 7.19 | |
Look-back period | |||
At least 6 months | 573 (75.8%) | 727,800 (54.8%) | |
At least 12 months | 513 (67.9%) | 638,042 (48.0%) | |
At least 18 months | 452 (59.8%) | 638,042 (48.0%) | |
At least 24 months | 404 (53.4%) | 481,827 (36.3%) | |
At least 36 months | 325 (43.0%) | 249,674 (18.8%) | |
Number of distinct symptoms | < 0.001 | ||
Mean (SD) | 5 (4) | 2 (2) | |
Min | 0 | 0 | |
Median (Q1–Q3) | 4 (2–7) | 1 (0–2) | |
Max | 19 | 25 | |
GD treatment | |||
Untreated | 0% | ||
Treated | 0% | ||
Rare disease history | < 0.001 | ||
0 | 756 (100.0%) | 1,327,978 (100.0%) | |
1 | 0 (0%) | 22 (0%) | |